Literature DB >> 10092086

CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells.

J H Fraser1, M Rincón, K D McCoy, G Le Gros.   

Abstract

CTLA4 is currently viewed as a late-appearing T cell surface receptor which is able to inhibit the proliferation of activated T cells. We sought to identify how CTLA4 ligation exerts these anti-proliferative effects by studying its influence on the activities of the relevant nuclear transcription factors AP-1, NFAT and NF-kappaB. We found that cross-linking CTLA4 on activated T cells completely blocks AP-1 and NFAT transcription factor activity before any effects on T cell proliferation can be observed, with NF-kappaB activity affected to a lesser degree. The suppression of AP-1 and NFAT transcriptional activity correlates with reduced levels of AP-1 and NFAT DNA binding as early as 10 h after T cell activation, prior to detectable up-regulation of CTLA4 on the T cell surface. Additionally, inhibitory effects on T cell proliferation only occurred when CTLA4 molecules were ligated in proximity to signaling TCR complexes, and inhibition of transcription factor DNA binding and activity was observed in the absence of CD28 stimulation. CTLA4 can thus act early during T cell activation to reduce the activity of several key nuclear transcription factors important for continued T cell proliferation and differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092086     DOI: 10.1002/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 2.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Immunological decision-making: how does the immune system decide to mount a helper T-cell response?

Authors:  Gerard E Kaiko; Jay C Horvat; Kenneth W Beagley; Philip M Hansbro
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

4.  Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.

Authors:  Julian Schulze Zur Wiesch; Adriana Thomssen; Philip Hartjen; Ilona Tóth; Clara Lehmann; Dirk Meyer-Olson; Kristina Colberg; Sebastian Frerk; Dalia Babikir; Stefan Schmiedel; Olaf Degen; Stefan Mauss; Jürgen Rockstroh; Schlomo Staszewski; Pavel Khaykin; Alexander Strasak; Ansgar W Lohse; Gerd Fätkenheuer; Joachim Hauber; Jan van Lunzen
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 5.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

6.  Cytotoxic T lymphocyte-associated antigen-4 inhibits integrin-mediated stimulation.

Authors:  Lucia Gatta; Gabriella Calviello; Fiorella Di Nicuolo; Luigia Pace; Vanessa Ubaldi; Gino Doria; Claudio Pioli
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 7.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

8.  Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4.

Authors:  Tara J Dillon; Kendall D Carey; Scott A Wetzel; David C Parker; Philip J S Stork
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

Review 9.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 10.  CTLA-4 trafficking and surface expression.

Authors:  Elke Valk; Christopher E Rudd; Helga Schneider
Journal:  Trends Immunol       Date:  2008-05-09       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.